ES2415665T3 - Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau - Google Patents

Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau Download PDF

Info

Publication number
ES2415665T3
ES2415665T3 ES05755789T ES05755789T ES2415665T3 ES 2415665 T3 ES2415665 T3 ES 2415665T3 ES 05755789 T ES05755789 T ES 05755789T ES 05755789 T ES05755789 T ES 05755789T ES 2415665 T3 ES2415665 T3 ES 2415665T3
Authority
ES
Spain
Prior art keywords
tau protein
tau
phosphorylation
protein
sites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05755789T
Other languages
English (en)
Spanish (es)
Inventor
Malcolm Ward
Helen Byers
Brian Henry Anderton
Pascal Derkinderen
Christopher Hugh Reynolds
Ritchie Williamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King's College London
Proteome Sciences PLC
Original Assignee
King's College London
Proteome Sciences PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King's College London, Proteome Sciences PLC filed Critical King's College London
Application granted granted Critical
Publication of ES2415665T3 publication Critical patent/ES2415665T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
ES05755789T 2004-06-21 2005-06-21 Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau Expired - Lifetime ES2415665T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58090104P 2004-06-21 2004-06-21
US580901P 2004-06-21
PCT/GB2005/002475 WO2005123048A2 (en) 2004-06-21 2005-06-21 Screening methods using c-abl, fyn and syk in combination with tau protein

Publications (1)

Publication Number Publication Date
ES2415665T3 true ES2415665T3 (es) 2013-07-26

Family

ID=35064772

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05755789T Expired - Lifetime ES2415665T3 (es) 2004-06-21 2005-06-21 Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau

Country Status (8)

Country Link
US (3) US8367360B2 (enExample)
EP (2) EP2441847B1 (enExample)
JP (3) JP5058792B2 (enExample)
AU (1) AU2005253776B8 (enExample)
CA (1) CA2571614C (enExample)
DK (1) DK1794313T3 (enExample)
ES (1) ES2415665T3 (enExample)
WO (1) WO2005123048A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019273A2 (en) * 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
DE602006004196D1 (de) * 2006-06-01 2009-01-22 Cellzome Ag Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung
US20100159477A1 (en) * 2006-07-13 2010-06-24 Peter Hornbeck Reagents for the detection of protein phosphorylation in signaling pathways
WO2008057599A2 (en) * 2006-11-10 2008-05-15 Intra-Cellular Therapies, Inc. Methods for the treatment of abeta related disorders and compositions therefor
WO2008145789A1 (es) * 2007-05-28 2008-12-04 Pontificia Universidad Catolica De Chile Uso de compuestos derivados de benzamidina metanosulfonato o su sal farmacéuticamente aceptable, por ejemplo mesilato de imatinib, para preparar un medicamento para el tratamiento de la enfermedad neurodegenerativa de niemann pick de tipo c ( npc).
WO2009143556A1 (en) * 2008-05-30 2009-12-03 The University Of Sydney TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION
WO2010118055A1 (en) 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
RU2012107457A (ru) 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
EP2485733A4 (en) * 2009-10-09 2014-06-18 Afraxis Holdings Inc METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US20130071330A1 (en) * 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
SG192596A1 (en) 2011-02-02 2013-09-30 Cognition Therapeutics Inc Isolated compounds from turmeric oil and methods of use
CA2866392C (en) 2012-03-30 2023-10-24 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
DK2844256T3 (da) * 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
EP2852388A4 (en) * 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
KR101582852B1 (ko) * 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
JP2014147365A (ja) * 2013-02-04 2014-08-21 Osaka City Univ オリゴヌクレオチド構造体および遺伝子発現抑制方法
BR112015022156A2 (pt) 2013-03-14 2017-11-14 Isis Pharmaceuticals Inc composições e métodos para modular a expressão de tau
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
JP6342627B2 (ja) * 2013-08-02 2018-06-13 国立大学法人 東京大学 筋萎縮性側索硬化症の新規病因遺伝子
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
PT3116911T (pt) * 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
EP3368032A1 (en) * 2015-10-28 2018-09-05 AB Science Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
JP2017131191A (ja) * 2016-01-29 2017-08-03 国立大学法人京都大学 疾患の予防及び／又は治療剤のスクリーニング方法
MD3519572T2 (ro) 2016-09-29 2024-03-31 Biogen Ma Inc Compuși și procedee de reducere a expresiei Tau
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
JPWO2018216705A1 (ja) * 2017-05-23 2020-03-26 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
JP7197864B2 (ja) * 2017-05-31 2022-12-28 公立大学法人名古屋市立大学 アルツハイマー病バイオマーカー
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
SG11202008895WA (en) * 2018-03-13 2020-10-29 Janssen Pharmaceutica Nv Modified oligonucleotides for use in treatment of tauopathies
CN120040470A (zh) 2018-11-20 2025-05-27 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN110702665B (zh) * 2019-11-14 2022-03-22 济南大学 一种纸基耦合增强拉曼传感器制备及其在大田软海绵酸检测中的应用
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US20260097056A1 (en) * 2022-09-20 2026-04-09 University Of Virginia Patent Foundation Syk activators and inhibitors in neurodegenerative diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5514778A (en) * 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods

Also Published As

Publication number Publication date
WO2005123048A2 (en) 2005-12-29
JP2014198054A (ja) 2014-10-23
AU2005253776A8 (en) 2012-02-02
WO2005123048A3 (en) 2006-03-30
EP2441847B1 (en) 2015-09-23
US20080103107A1 (en) 2008-05-01
DK1794313T3 (da) 2013-07-22
EP2441847A2 (en) 2012-04-18
US20130123133A1 (en) 2013-05-16
US8367360B2 (en) 2013-02-05
AU2005253776A1 (en) 2005-12-29
JP5668201B2 (ja) 2015-02-12
JP5058792B2 (ja) 2012-10-24
AU2005253776B2 (en) 2011-09-29
CA2571614A1 (en) 2005-12-29
CA2571614C (en) 2016-12-06
US20160186233A1 (en) 2016-06-30
AU2005253776B8 (en) 2012-02-02
EP1794313A2 (en) 2007-06-13
EP1794313B1 (en) 2013-05-15
JP2008504022A (ja) 2008-02-14
EP2441847A3 (en) 2012-07-25
JP2012024094A (ja) 2012-02-09

Similar Documents

Publication Publication Date Title
US8367360B2 (en) Method of screening for inhibitors of tau protein phosphororylation by tyrosine kinase c-Abl
Giusto et al. Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins
Mbefo et al. Phosphorylation of synucleins by members of the Polo-like kinase family
Brunden et al. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Plattner et al. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation
Chou et al. GSK3beta-mediated Drp1 phosphorylation induced elongated mitochondrial morphology against oxidative stress
McPhie et al. DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3
Koizumi et al. DCLK1 phosphorylates the microtubule‐associated protein MAP7D1 to promote axon elongation in cortical neurons
US9605054B2 (en) Composition and method for treating a tauopathy
Liao et al. TTBK2: a tau protein kinase beyond tau phosphorylation
Merrill et al. N‐terminal phosphorylation of protein phosphatase 2A/Bβ2 regulates translocation to mitochondria, dynamin‐related protein 1 dephosphorylation, and neuronal survival
Zhou et al. Distinct and sequential re-replication barriers ensure precise genome duplication
US20150051097A1 (en) Methods for Screening Inhibitors of Tau Phosphorylation By Casein Kinase I
Martín-Doncel et al. VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes
Peng et al. Microtubule‐associated proteins and enzymes modifying tubulin
Botta et al. MBNL142 and MBNL143 gene isoforms, overexpressed in DM1-patient muscle, encode for nuclear proteins interacting with Src family kinases
Chu et al. The influence of 5-lipoxygenase on Alzheimer’s disease-related tau pathology: in vivo and in vitro evidence
WO2015157514A1 (en) Ribosomal protein s15 phosphorylation mediates lrrk2 neurodegeneration in parkinson's disease
US20080242608A1 (en) Methods and compositions for treating and preventing neurologic disorders
AU2005304638A1 (en) Methods and compositions for treating cellular proliferative diseases
Desai et al. ASH: a new protein domain on the horizon
Class et al. Inventors: Malcolm Ward (Surrey, GB) Proteome Science Plc (Surrey, GB) Helen Byers (Surrey, GB) King'S College London (London, GB) Brian Henry Anderton (London, GB) Pascal Derkinderen (London, GB) Christipher Hugh Reynolds (London, GB) Ritchie Williamson (London, GB) Assignees: KING'S COLLEGE LONDON PROTEOME SCIENCES PLC
Shomali Characterization of small molecule inhibitors of PINK1
Tetteh Regulation of TRPM7 by CNNM2 and interacting partners
Grant The Role of CaMK1D in Alzheimer's Disease